GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Abstract Background Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. Methods/design G...

Full description

Bibliographic Details
Main Authors: Jamie B. Oughton, Laura Collett, Dena R. Howard, Anna Hockaday, Talha Munir, Kathryn McMahon, Lucy McParland, Claire Dimbleby, David Phillips, Andy C. Rawstron, Peter Hillmen
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Trials
Subjects:
Chronic lymphocytic leukaemia (CLL)
Obinutuzumab
GA-101
Consolidation
Phase II/III trial
Minimal residual disease (MRD)
Online Access:http://link.springer.com/article/10.1186/s13063-017-2107-0

Internet

http://link.springer.com/article/10.1186/s13063-017-2107-0

Similar Items